• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Changes at the top for Zeiss ophthalmic biz

Changes at the top for Zeiss ophthalmic biz

March 9, 2020 By Sean Whooley

zeiss-logoCarl Zeiss Meditec announced today that Jim Mazzo will retire from his role as president of ophthalmic devices and head of the ophthalmic devices strategic business unit.

Mazzo is slated to continue supporting Zeiss as an advisor, having spent over 40 years in the ophthalmic industry and more than three with Zeiss. His retirement is set to be made effective on May 1.

“Jim has been an integral part of growing our global ophthalmology business and has strengthened a customer-oriented mindset and service into the Zeiss culture,” Zeiss president & CEO Ludwin Monz said in a news release. “His leadership, insights and guidance have been instrumental in building a strong team, while creating a global approach through regional alignment and increasing visibility of professional education for customers. We thank him for his knowledge, leadership and many contributions in helping advance eye care.”

Euan Thomson, a veteran of more than 30 years in the medtech space, has been tabbed as the successor to Mazzo in both roles. Thomson currently serves as the head of the digital business unit for Zeiss, and he is set to continue guiding digital activities.

Before joining Zeiss in September 2019, Thomson held the role of president & CEO at Photoelectron Corporation and Accuray (NSDQ:ARAY) before that. He also worked in venture capital, but most recently led the digital technology development unit at Johnson & Johnson (NYSE:JNJ).

“I am very proud of what we have accomplished for customers and employees and pleased to hand over responsibility to Euan and the team,” Mazzo said in the news release. “With this team, we have achieved record-breaking growth. I look forward to continuing my support for Zeiss as an advisor and my involvement in the ophthalmic community.”

“I believe in the great work ZEISS is doing for patients around the world,” added Thomson. “I look forward to continuing the mission to better serve ophthalmic customers and their patients and to supporting and shaping the company’s strategic goals.”

Zeiss also noted that Andrew Chang, the current head of sales for ophthalmic devices, will be appointed as president of Carl Zeiss Meditec and continue to lead the global ophthalmic sales organizations.

Filed Under: Business/Financial News, Optical/Ophthalmic Tagged With: Carl Zeiss Meditec, Personnel Moves

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy